TransThera Sciences (HKG:2617) launched its initial public offering in Hong Kong that seeks to raise up to HK$200.9 million, according to a Friday Hong Kong bourse filing.
The clinical-stage biopharmaceutical firm is offering as much as 15,281,000 shares at an indicative price of HK$13.15 each.
TransThera secured five cornerstone investors, including Jiangbei Pharmaceutical, Akeso (HKG:9926), Sinohsc Honest, Pharmablock Horizon, and Kelingan, which committed to subscribe for a combined HK$130.0 million worth of IPO shares, representing around 64.1% of the offering.
The issuer expects to determine its offer price and disclose the allocations on June 20. It will then start trading on the Hong Kong bourse on June 23, according to a prospectus filing.
Proceeds from the deal will primarily fund a multiregional Phase III trial of its core product Tinengotinib, with remaining funds allocated to general working capital and corporate purposes.
CLSA, Huatai Financial, BOCOM International, BOCI Asia, CMB International, SPDB International, and TradeGo Markets are acting as joint bookrunners.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。